Identification of genes that elicit disuse muscle atrophy via the transcription factors p50 and Bcl-3.
Skeletal muscle atrophy is a debilitating condition associated with weakness, fatigue, and reduced functional capacity. Nuclear factor-kappaB (NF-κB) transcription factors play a critical role in atrophy. Knockout of genes encoding p50 or the NF-κB co-transactivator, Bcl-3, abolish disuse atrophy and thus they are NF-κB factors required for disuse atrophy. We do not know however, the genes targeted by NF-κB that produce the atrophied phenotype. Here we identify the genes required to produce disuse atrophy using gene expression profiling in wild type compared to Nfkb1 (gene encodes p50) and Bcl-3 deficient mice. There were 185 and 240 genes upregulated in wild type mice due to unloading, that were not upregulated in Nfkb1⁻/⁻ and Bcl-3⁻/⁻ mice, respectively, and so these genes were considered direct or indirect targets of p50 and Bcl-3. All of the p50 gene targets were contained in the Bcl-3 gene target list. Most genes were involved with protein degradation, signaling, translation, transcription, and transport. To identify direct targets of p50 and Bcl-3 we performed chromatin immunoprecipitation of selected genes previously shown to have roles in atrophy. Trim63 (MuRF1), Fbxo32 (MAFbx), Ubc, Ctsl, Runx1, Tnfrsf12a (Tweak receptor), and Cxcl10 (IP-10) showed increased Bcl-3 binding to κB sites in unloaded muscle and thus were direct targets of Bcl-3. p50 binding to the same sites on these genes either did not change or increased, supporting the idea of p50:Bcl-3 binding complexes. p65 binding to κB sites showed decreased or no binding to these genes with unloading. Fbxo9, Psma6, Psmc4, Psmg4, Foxo3, Ankrd1 (CARP), and Eif4ebp1 did not show changes in p65, p50, or Bcl-3 binding to κB sites, and so were considered indirect targets of p50 and Bcl-3. This work represents the first study to use a global approach to identify genes required to produce the atrophied phenotype with disuse.
Department of Health Sciences, Boston University, Boston, Massachusetts, United States of America.
Chia-Ling
CL
Wu
Susan C
SC
Kandarian
Robert W
RW
Jackman
D000818:Animals; D000081242:B-Cell Lymphoma 3 Protein; D001665:Binding Sites; D020869:Gene Expression Profiling; D051379:Mice; D018345:Mice, Knockout; D009133:Muscular Atrophy / Q000209:etiology / Q000235:genetics*; D020966:Muscular Disorders, Atrophic / Q000235:genetics; D052002:NF-kappa B p50 Subunit / Q000235:genetics* / Q000378:metabolism; D011485:Protein Binding; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism; D019892:eIF-2 Kinase
D000081242:B-Cell Lymphoma 3 Protein; C000631345:Bcl3 protein, mouse; D052002:NF-kappa B p50 Subunit; D011518:Proto-Oncogene Proteins; D014157:Transcription Factors; C073701:Nfkb1 protein, mouse; D019892:eIF-2 Kinase
Muscle Nerve. 2006 Feb;33(2):155-65
16228971
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5
11717410
J Clin Invest. 2004 Nov;114(10):1504-11
15546001
Cell. 2004 Aug 20;118(4):453-64
15315758
J Biol Chem. 1993 Mar 25;268(9):6677-88
8454640
Mol Cell Biol. 1996 Apr;16(4):1342-8
8657107
Physiology (Bethesda). 2008 Jun;23:160-70
18556469
Free Radic Biol Med. 2008 Jan 15;44(2):202-14
18191756
J Clin Invest. 2007 Apr;117(4):889-901
17380205
FASEB J. 2007 Feb;21(2):427-37
17172638
Biochem J. 1996 May 15;316 ( Pt 1):65-72
8645234
Nucl Recept. 2005 Oct 03;3:3
16197558
Cell. 2004 Oct 15;119(2):285-98
15479644
Eur J Cancer. 2010 Jan;46(1):191-7
19857958
FASEB J. 2003 Mar;17(3):386-96
12631578
Biochem J. 2010 Mar 15;427(1):171-8
20088826
Oncogene. 2006 Oct 30;25(51):6680-4
17072321
Am J Pathol. 2000 Jun;156(6):2103-10
10854231
Curr Protoc Bioinformatics. 2008 Jun;Chapter 7:Unit 7.12
18551415
Am J Physiol. 1993 May;264(5 Pt 1):C1308-15
8388635
J Cell Biol. 2010 Mar 22;188(6):833-49
20308426
J Mol Biol. 2005 Jul 22;350(4):713-22
15967462
Genes Dev. 1993 Jul;7(7B):1354-63
8330739
J Clin Invest. 2006 Nov;116(11):2945-54
17080195
Ageing Res Rev. 2010 Jul;9(3):298-314
19903538
J Physiol. 2003 Aug 15;551(Pt 1):33-48
12844509
FASEB J. 2007 Jan;21(1):140-55
17116744
FASEB J. 2009 Feb;23(2):362-70
18827022
FASEB J. 2007 Jun;21(8):1857-69
17314137
Am J Physiol Cell Physiol. 2007 Jan;292(1):C372-82
16928772
Cancer Cell. 2005 Nov;8(5):421-32
16286249
Genes Dev. 2005 Jul 15;19(14):1715-22
16024660
FASEB J. 2002 Apr;16(6):529-38
11919155
Cell. 2004 Apr 30;117(3):399-412
15109499
Science. 2001 Nov 23;294(5547):1704-8
11679633
Int Rev Immunol. 2008;27(5):375-87
18853344
J Cell Biol. 2009 Jun 15;185(6):1083-95
19506036
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19090-5
20956306
Cell Metab. 2007 Nov;6(5):376-85
17983583
Nucleic Acids Res. 2004 Feb 26;32(4):1372-81
14988425
EMBO J. 1999 Sep 1;18(17):4766-78
10469655
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
12883005
Cell. 2008 Feb 8;132(3):344-62
18267068
Nat Rev Mol Cell Biol. 2007 Jan;8(1):49-62
17183360